Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results